Company Analysis CSPC Pharmaceutical Group Limited
1. Summary
Advantages
- Price (4.99 HK$) is less than fair price (6.39 HK$)
- Dividends (5.98%) are higher than the sector average (5.54%).
- The company's current efficiency (ROE=18.53%) is higher than the sector average (ROE=5.19%)
Disadvantages
- The stock's return over the last year (-31.03%) is lower than the sector average (-28.88%).
- Current debt level 1.26% has increased over 5 years from 0.3461%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| CSPC Pharmaceutical Group Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.1% | -3.5% | 1.9% |
| 90 days | -8.4% | -13.4% | -2.6% |
| 1 year | -31% | -28.9% | 22.9% |
1093 vs Sector: CSPC Pharmaceutical Group Limited has slightly underperformed the "Healthcare" sector by -2.16% over the past year.
1093 vs Market: CSPC Pharmaceutical Group Limited has significantly underperformed the market by -53.98% over the past year.
Stable price: 1093 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 1093 with weekly volatility of -0.5968% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (4.99 HK$) is lower than the fair price (6.39 HK$).
Price significantly below the fair price: The current price (4.99 HK$) is 28.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (12.72) is lower than that of the sector as a whole (35.42).
P/E vs Market: The company's P/E (12.72) is lower than that of the market as a whole (26.67).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.13) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (2.13) is higher than that of the market as a whole (-11.94).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.38) is lower than that of the sector as a whole (7.59).
P/S vs Market: The company's P/S indicator (2.38) is lower than that of the market as a whole (2.77).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (7.12) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (7.12) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 11.63% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (11.63%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-0.8806%).
5.4. ROE
ROE vs Sector: The company's ROE (18.53%) is higher than that of the sector as a whole (5.19%).
ROE vs Market: The company's ROE (18.53%) is higher than that of the market as a whole (6.3%).
5.5. ROA
ROA vs Sector: The company's ROA (13.34%) is higher than that of the sector as a whole (3.47%).
ROA vs Market: The company's ROA (13.34%) is higher than that of the market as a whole (3.39%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 5.98% is higher than the average for the sector '5.54%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 5.98% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 5.98% has been growing over the last 5 years. Growth over 10 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (46.42%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
